{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:15:25Z","timestamp":1773296125998,"version":"3.50.1"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Genotypic tropism testing methods are emerging as the first step before prescription of the CCR5 antagonist maraviroc (MVC) to HIV-infected patients in Europe. Studies validating genotypic tests have included other active drugs that could have potentially convoluted the effects of MVC. The maraviroc clinical test (MCT) is an\n            <jats:italic>in vivo<\/jats:italic>\n            drug sensitivity test based on the virological response to a short-term exposure to MVC monotherapy. Thus, our aim was to compare the results of genotypic tropism testing methods with the short-term virological response to MVC monotherapy. A virological response in the MCT was defined as a \u22651-log\n            <jats:sub>10<\/jats:sub>\n            decrease in HIV RNA or undetectability after 8 days of drug exposure. Seventy-three patients undergoing the MCT were included in this study. We used both standard genotypic methods (\n            <jats:italic>n<\/jats:italic>\n            = 73) and deep sequencing (\n            <jats:italic>n<\/jats:italic>\n            = 27) on MCT samples at baseline. For the standard methods, the most widely used genotypic algorithms for analyzing the V3 loop sequence, geno2pheno and PSSM, were used. For deep sequencing, the geno2pheno algorithm was used with a false-positive rate cutoff of 3.5. The discordance rates between the standard genotypic methods and the virological response were approximately 20% (including mostly patients without a virological response). Interestingly, these discordance rates were similar to that obtained from deep sequencing (18.5%). The discordance rates between the genotypic methods (tropism assays predictive of the use of the CCR5 coreceptor) and the MCT (\n            <jats:italic>in vivo<\/jats:italic>\n            MVC sensitivity assay) indicate that the algorithms used by genotypic methods are still not sufficiently optimized.\n          <\/jats:p>","DOI":"10.1128\/aac.05857-11","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T06:15:55Z","timestamp":1323152155000},"page":"1202-1207","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods"],"prefix":"10.1128","volume":"56","author":[{"given":"A.","family":"Gonzalez-Serna","sequence":"first","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Infectious Diseases Service, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"McGovern","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"},{"name":"University of British Columbia, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. R.","family":"Harrigan","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"},{"name":"University of British Columbia, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Vidal","sequence":"additional","affiliation":[{"name":"Hospital Universitari Joan XXIII, IISPV, Universitat Rovira I Virgili, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F. Y.","family":"Poon","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ferrando-Martinez","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immuno-Biology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Abad","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Infectious Diseases Service, Virgen del Roc\u00edo University Hospital, Seville, Spain"},{"name":"Biochemistry Department, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Genebat","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Infectious Diseases Service, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leal","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Infectious Diseases Service, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ruiz-Mateos","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Infectious Diseases Service, Virgen del Roc\u00edo University Hospital, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.657"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21425"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00333-10"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181734f0e"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_3_3_7_2","volume-title":"13th Eur. AIDS Conf.","author":"Genebat M","year":"2011","unstructured":"GenebatM. 2011. Maraviroc clinical test (MCT) effectiveness for CCR5 prescription in clinical practice, abstr PE7.9\/8. Abstr. 13th Eur. AIDS Conf., Belgrade, Serbia."},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.antiviral.2010.11.015","article-title":"Discordance rates between Trofile(\u00ae) test and short-term virological response to maraviroc","volume":"89","author":"Genebat M","year":"2011","unstructured":"GenebatM. 2011. Discordance rates between Trofile(\u00ae) test and short-term virological response to maraviroc. Antiviral Res. 89:182\u2013185.","journal-title":"Antiviral Res"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkp293","article-title":"Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients","volume":"64","author":"Genebat M","year":"2009","unstructured":"GenebatM. 2009. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 64:845\u2013859.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016210793499295"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq379"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00953-10"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/QAD.0b013e32834113f9","article-title":"Genotypic tropism testing: evidence-based or leap of faith?","volume":"25","author":"Harrigan PR","year":"2011","unstructured":"HarriganPR GerettiAM. 2011. Genotypic tropism testing: evidence-based or leap of faith? AIDS 25:257\u2013264.","journal-title":"AIDS"},{"key":"e_1_3_3_14_2","first-page":"104","article-title":"Predicting HIV-1 coreceptor usage with sequence analysis","volume":"5","author":"Jensen MA","year":"2003","unstructured":"JensenMA van't WoutAB. 2003. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 5:104\u2013112.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00385-07"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282ef81ea"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.04.035"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3791\/2531"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833e6cfb"},{"key":"e_1_3_3_20_2","volume-title":"8th Eur. HIV Drug Resist. Workshop","author":"Obermeier M","year":"2010","unstructured":"ObermeierM. 2010. Tropism testing from proviral DNA\u2014analysis of a subgroup from the Berlin maraviroc cohort, abstr 23. Abstr. 8th Eur. HIV Drug Resist. Workshop, Sorrento, Italy."},{"key":"e_1_3_3_21_2","first-page":"135","article-title":"Genotypic determination of HIV tropism\u2014clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists","volume":"12","author":"Poveda E","year":"2010","unstructured":"PovedaE. 2010. Genotypic determination of HIV tropism\u2014clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 12:135\u2013148.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp063"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1742-4690-7-56","article-title":"Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping","volume":"7","author":"Prosperi MC","year":"2010","unstructured":"ProsperiMC. 2010. Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 7:56.","journal-title":"Retrovirology"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.11.018"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr224"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00148-10"},{"key":"e_1_3_3_27_2","first-page":"94","article-title":"An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies","volume":"3","author":"Reeves JD","year":"2009","unstructured":"ReevesJD CoakleyE PetropoulosCJ WhitcombJM. 2009. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94\u2013102.","journal-title":"J. Viral Entry"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-89"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00753-11"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAI.0b013e3181fc012b","article-title":"A highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining V3 loop sequences interpretation and clinical parameters","volume":"56","author":"S\u00e1nchez V","year":"2011","unstructured":"S\u00e1nchezV. 2011. A highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining V3 loop sequences interpretation and clinical parameters. J. Acquir. Immune Defic. Syndr. 56:51\u201358.","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1128\/JCM.01204-10","article-title":"Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay","volume":"4","author":"S\u00e1nchez V","year":"2010","unstructured":"S\u00e1nchezV. 2010. Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J. Clin. Microbiol. 4:4135\u20134139.","journal-title":"J. Clin. Microbiol"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1093\/jac\/dkq381","article-title":"Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients","volume":"65","author":"Secl\u00e9n E","year":"2010","unstructured":"Secl\u00e9nE. 2010. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. Antimicrob. Chemother. 65:2502\u20132504.","journal-title":"Antimicrob. Chemother"},{"key":"e_1_3_3_33_2","volume-title":"8th Eur. HIV Drug Resist. Workshop","author":"Sierra S","year":"2010","unstructured":"SierraS. 2010. Tropism determination and clinical outcome of 61 patients under maraviroc treatment, abstr 20. Abstr. 8th Eur. HIV Drug Resist. Workshop, Sorrento, Italy."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq030"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d0558f"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005683"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/vim.2006.19.759","article-title":"Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure","volume":"19","author":"Vallejo A","year":"2006","unstructured":"VallejoA. 2006. Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure. Viral Immunol. 19:759\u2013767.","journal-title":"Viral Immunol"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkq458","article-title":"Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment","volume":"66","author":"Vandekerckhove L","year":"2010","unstructured":"VandekerckhoveL. 2010. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J. Antimicrob. Chemother. 66:265\u2013272.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_3_39_2","volume-title":"8th Eur. HIV Drug Resist. Workshop","author":"Van Lelyveld S","year":"2010","unstructured":"Van LelyveldS. 2010. Correlation of clinical outcome of maraviroc treatment with different methods to determine HIV tropism: genotypic assays, MT-2 assay and Trofile, abstr. 41. Abstr. 8th Eur. HIV Drug Resist. Workshop, Sorrento, Italy."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00853-06"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05857-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05857-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:17:30Z","timestamp":1645481850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05857-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1128\/AAC.05857-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05857-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"2011-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}